Related Experiment Video

Updated: May 30, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Novel therapeutic targets in non-small cell lung cancer

Filip Janku1, Ignacio Garrido-Laguna, Lubos B Petruzelka

  • 1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. fjanku@mdanderson.org

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|August 19, 2011
PubMed

Insights

Personalized medicine is revolutionizing non-small cell lung cancer treatment. Novel targeted therapies identify specific molecular targets, offering new hope for this difficult-to-treat malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Traditional non-small cell lung cancer (NSCLC) treatments are being replaced by personalized medicine.
  • Targeted therapies offer improved outcomes by focusing on specific molecular targets within patient subpopulations.
  • Key molecular targets driving NSCLC progression include EGFR, MET, VEGF, KRAS, HER2, ALK, PIK3CA, BRAF, and IGF-1R.

Purpose of the Study:

  • To review molecular targets in NSCLC currently in development or clinical application.
  • To discuss the implications of these targets for novel anticancer therapy development.
  • To highlight the shift from a one-size-fits-all approach to precision medicine in NSCLC.

Main Methods:

  • Literature review of targeted therapies and molecular targets in NSCLC.
  • Analysis of currently approved and investigational targeted treatments.
  • Discussion of the role of specific molecular targets in cancer signaling pathways.

Main Results:

  • Several targeted therapies, including EGFR inhibitors and anti-VEGF antibodies, are approved for NSCLC.
  • Therapies targeting MET, VEGFR, HER2, PIK3CA, and IGF-1R are in clinical trials.
  • Identification of numerous molecular targets crucial for NSCLC development and progression.

Conclusions:

  • Personalized medicine and targeted therapies represent a significant advancement in NSCLC treatment.
  • Understanding molecular targets is key to developing effective novel anticancer strategies.
  • The review provides insights into the evolving landscape of NSCLC therapeutic development.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...